Drug · CHEMBL885
EMTRICITABINE
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. EMTRICITABINE. Drugs and targets, record CHEMBL885. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL885
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Brand names
Emtricitabine component of atripla, Emtricitabine component of biktarvy, Emtricitabine component of complera, Emtricitabine component of descovy, Emtricitabine component of eviplera, Emtricitabine component of genvoya, Emtricitabine component of odefsey, Emtricitabine component of stribild, Emtricitabine component of symtuza, Emtricitabine component of truvada, Emtriva
- ChEMBL
- Other names
- (-)-FTC, (-)-emtricitabine, 524-W-91, 524W91, BW-524W91, Coviracil, Emtricitabina, Emtricitabine, (-)-, Emtricitabinum, FTC-(-)
- ChEMBL
- Open Targets' highest stage
- Approval, for 3 of its 23 diseases, from ATC, DailyMed, EMA Human Drugs, FDA, PMDA and TTD
- Open Targets
Targets0
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
None in this release.
Diseases23
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
1 to 10 of 23Source Open Targets
See all 23 diseasesTrials554
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 3 more rest on that reading alone and are shown because the trials' posted result groups or NLM's indexing of their papers name the drug. 5 more that Open Targets linked to it are not shown, since the release's checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT02842086 | Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex With Men and Are At Risk of HIV-1 Infection | Phase 3 | 5,399 | 2020-03-17 | emtricitabine | Its name | ClinicalTrials.gov |
| NCT04994509 | Pre-Exposure Prophylaxis Study of Lenacapavir and Emtricitabine/Tenofovir Alafenamide in Adolescent Girls and Young Women at Risk of HIV Infection | Phase 3 | 5,368 | 2025-06-19 | emtricitabine | Its name | ClinicalTrials.gov |
| NCT00705679 | Safety and Effectiveness of TFV 1% Gel, TDF Tablets, and FTC/TDF Tablets in Preventing HIV in Women | Phase 2 | 5,029 | 2016-02-10 | emtricitabine/tenofovir disoproxil fumarate | A combination that names it | ClinicalTrials.gov |
| NCT00557245 | Pre-Exposure Prophylaxis to Prevent HIV-1 Acquisition Within HIV-1 Discordant Couples | Phase 3 | 4,758 | 2014-11-27 | emtricitabine | Its name | ClinicalTrials.gov |
| NCT02720094 | Injectable Cabotegravir Compared to TDF/FTC For PrEP in HIV-Uninfected Men and Transgender Women Who Have Sex With Men | Phase 2/3 | 4,570 | 2023-11-24 | emtricitabine | Its name | ClinicalTrials.gov |
| NCT01061151 | Evaluating Strategies to Reduce Mother-to-Child Transmission of HIV Infection in Resource-Limited Countries | Phase 3 | 3,747 | 2018-02-09 | emtricitabine-tenofovir disoproxil fumarate | A combination that names it | ClinicalTrials.gov |
| NCT00074581 | Preventing Sexual Transmission of HIV With Anti-HIV Drugs | Phase 3 | 3,526 | 2016-10-31 | emtricitabine | Its name | ClinicalTrials.gov |
| NCT03164564 | Evaluating the Safety and Efficacy of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women | Phase 3 | 3,224 | 2023-03-28 | emtricitabine | Its name | ClinicalTrials.gov |
| NCT00458393 | Emtricitabine/Tenofovir Disoproxil Fumarate for HIV Prevention in Men | Phase 3 | 2,499 | 2018-01-24 | emtricitabine | Its name | ClinicalTrials.gov |
| NCT00625404 | FEM-PrEP (Truvada®): Study to Assess the Role of Truvada® in Preventing HIV Acquisition in Women | Phase 3 | 2,120 | 2014-04-16 | emtricitabine | Its name | ClinicalTrials.gov |
1 to 10 of 554
See all 554 trialsComparisons in its trials198
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Descovy (DVY) vs Truvada (TVD): deaths from any cause | 3 of 2,694 | 3 of 2,693 | 5,387 | NCT02842086 | Trial comparisons |
| Descovy (DVY) vs Truvada (TVD): serious adverse events | 202 of 2,694 | 186 of 2,693 | 5,387 | NCT02842086 | Trial comparisons |
| Cabotegravir vs TDF/FTC: deaths from any cause | 4 of 2,281 | 7 of 2,285 | 4,566 | NCT02720094 | Trial comparisons |
| Cabotegravir vs TDF/FTC: serious adverse events | 117 of 2,281 | 109 of 2,285 | 4,566 | NCT02720094 | Trial comparisons |
| Cabotegravir vs TDF/FTC: Number of Participants Experiencing Grade 2 or Higher Clinical and Laboratory Adverse Events | 2,106 of 2,280 | 2,116 of 2,282 | 4,562 | NCT02720094 | Trial comparisons |
| Cabotegravir vs TDF/FTC: Number of Participants With Grade 3 or 4 Liver-related Adverse Events (AEs) | 73 of 2,280 | 96 of 2,282 | 4,562 | NCT02720094 | Trial comparisons |
| Cabotegravir vs TDF/FTC: Number of Participants With Documented Incident HIV Infections During Steps 1 and 2 | 13 of 2,280 | 39 of 2,281 | 4,561 | NCT02720094 | Trial comparisons |
| Cabotegravir vs TDF/FTC: Number of Participants With Documented Incident HIV Infections in Step 2 | 8 of 2,114 | 37 of 2,079 | 4,193 | NCT02720094 | Trial comparisons |
Arm A: CAB + Placebo TDF/FTC + CAB LA vs Arm B: TDF/FTC + Placebo CAB + Placebo CAB LA: Number of Participants Who Experienced Grade 2 or Higher Clinical and Laboratory Adverse Events (AEs) in Steps 1 and 2 | 1,487 of 1,614 | 1,486 of 1,610 | 3,224 | NCT03164564 | Trial comparisons |
| Arm A: CAB + Placebo TDF/FTC + CAB LA vs Arm B: TDF/FTC + Placebo CAB + Placebo CAB LA: Number of Pariicipants With Documented Incident HIV Infections | 4 of 1,614 | 36 of 1,610 | 3,224 | NCT03164564 | Trial comparisons |
1 to 10 of 198
See all 198 comparisons in its trialsPapers from its trials672
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials10
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
| Test | Trials naming it as an outcome | As a primary outcome | Source |
|---|---|---|---|
| Category Fluency | 1 | 0 | ConductCognition |
| Clock Drawing Task | 1 | 0 | ConductCognition |
| Digit Span Test | 1 | 0 | ConductCognition |
| Go/No-Go Task | 1 | 1 | ConductCognition |
| Picture Naming Test | 1 | 0 | ConductCognition |
| Selective Reminding Task | 1 | 0 | ConductCognition |
| Short Story Recall | 1 | 0 | ConductCognition |
| Trail Making Test A | 1 | 0 | ConductCognition |
| Verbal Fluency | 1 | 1 | ConductCognition |
| Verbal Learning | 1 | 0 | ConductCognition |
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL885
GET https://conductscience.org/api/drugs/v1/CHEMBL885/diseases?page=2